NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

As this week's PR from SITC can be transformational, I wanted to step back and share what I see to be the larger breadth of Linda Power's vision and strategy unfolding before our eyes:

- Global company, global revenues, global manufacturing (not just US, Germany first, UK second, other EU countries to piggyback off the PEI and MHRA regulatory bodies, Israel)
- Patient first & Compassionate Use (55 person information arm for those not eligible for DCVAX-L P3, Israel, Germany, UK, cross-over design built into trials)
- Go Big (no BP partner, no 50%-70% dilution of future revenues for up-front cash to run P3 trials)
- Strategic partner Cognate (able to push forward and control critical R&D development, global production quality & approvals, and guard mfg secrets + provide a funding vehicle during this clinical trial phase NWBO is in)
- Immunotherapy cancer cure, SOC [interjecting my hope here: be low cost and disrupt the standard $100K+/yr pricing of cancer treatments that gouges the US healthcare system, relative to much much lower pricing elsewhere around the world]

Excerpt from one of my older posts for emphasis:

- even with lots of money, not many other companies could accomplish what NWBO management has accomplished during the same time frame. Not all CEOs have the vision to invest the time and money in the EU when time and money was so scarce for a small company like NWBO.
- even while operating on a shoestring budget and staff, NWBO has done what other companies could not. DCVAX-L is the "first" to get hospital exemption in Germany and for UK, the first product selected for the first step of a two-step process to receive early patient access likely in 2015, which leads to revenues.